Brokerages Set DocuSign, Inc. (NASDAQ:DOCU) Target Price at $92.45

Shares of DocuSign, Inc. (NASDAQ:DOCUGet Free Report) have received an average rating of “Hold” from the thirteen ratings firms that are presently covering the stock, Marketbeat Ratings reports. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $92.45.

DOCU has been the topic of several recent research reports. Citigroup increased their target price on DocuSign from $87.00 to $113.00 and gave the stock a “buy” rating in a research report on Friday, December 6th. Morgan Stanley raised their target price on DocuSign from $62.00 to $97.00 and gave the stock an “equal weight” rating in a research note on Friday, December 6th. Bank of America upped their price target on DocuSign from $60.00 to $68.00 and gave the company a “neutral” rating in a research report on Friday, September 6th. Robert W. Baird raised their price objective on shares of DocuSign from $59.00 to $100.00 and gave the company a “neutral” rating in a research report on Friday, December 6th. Finally, Jefferies Financial Group upped their target price on shares of DocuSign from $80.00 to $95.00 and gave the stock a “buy” rating in a report on Tuesday, December 3rd.

Get Our Latest Stock Report on DocuSign

DocuSign Trading Down 5.6 %

Shares of DOCU stock opened at $92.71 on Monday. The firm’s 50 day moving average is $79.83 and its 200 day moving average is $64.22. The stock has a market capitalization of $18.73 billion, a P/E ratio of 19.12, a PEG ratio of 8.72 and a beta of 0.92. DocuSign has a 12 month low of $48.70 and a 12 month high of $107.86.

Insider Buying and Selling at DocuSign

In other news, Director Teresa Briggs sold 534 shares of the company’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $94.60, for a total value of $50,516.40. Following the completion of the sale, the director now owns 7,736 shares of the company’s stock, valued at approximately $731,825.60. This represents a 6.46 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider James P. Shaughnessy sold 7,500 shares of the stock in a transaction on Wednesday, October 9th. The shares were sold at an average price of $67.83, for a total transaction of $508,725.00. Following the transaction, the insider now directly owns 43,301 shares in the company, valued at approximately $2,937,106.83. This represents a 14.76 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 660,737 shares of company stock worth $63,029,016 over the last 90 days. Corporate insiders own 1.66% of the company’s stock.

Institutional Investors Weigh In On DocuSign

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Itau Unibanco Holding S.A. bought a new position in DocuSign during the 3rd quarter worth approximately $28,000. Brooklyn Investment Group bought a new position in shares of DocuSign in the third quarter worth approximately $33,000. Reston Wealth Management LLC purchased a new position in shares of DocuSign in the third quarter worth $47,000. nVerses Capital LLC bought a new stake in DocuSign during the 2nd quarter valued at $48,000. Finally, Wilmington Savings Fund Society FSB bought a new stake in DocuSign during the 3rd quarter valued at $51,000. Institutional investors own 77.64% of the company’s stock.

DocuSign Company Profile

(Get Free Report

DocuSign, Inc provides electronic signature solution in the United States and internationally. The company provides e-signature solution that enables sending and signing of agreements on various devices; Contract Lifecycle Management (CLM), which automates workflows across the entire agreement process; Document Generation streamlines the process of generating new, custom agreements; and Gen for Salesforce, which allows sales representatives to automatically generate agreements with a few clicks from within Salesforce.

Recommended Stories

Analyst Recommendations for DocuSign (NASDAQ:DOCU)

Receive News & Ratings for DocuSign Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DocuSign and related companies with MarketBeat.com's FREE daily email newsletter.